[Click eStock] "JLKE, Targeting US Market with Stroke Specialized AI Solution"

Independent research firm Stunning Value Research analyzed on the 12th that JLKE will surpass the break-even point (BEP) in the fourth quarter of next year through its entry into the U.S. market.

Yeongdae Jeon, a researcher at Stunning Value Research, stated in the report, "JLKE utilizes its proprietary medical imaging analysis technology to provide solutions such as early disease diagnosis, reading assistance, lesion detection, and prognosis prediction," adding, "It has obtained 81 global approvals so far, including from the Korean MFDS, U.S. FDA, Japan PMDA, and European CE."

He explained, "Globally, 15 million people are newly diagnosed with stroke annually, with one person developing it every 2 seconds and one person dying every 6 seconds, which is a serious situation," and "According to research from Johns Hopkins University, stroke is the disease with the highest misdiagnosis rate, and if not treated timely, it is highly likely to lead to aftereffects."

In particular, the number of patients missing the golden time has doubled over the past 30 years, reaching about 100 million. JLKE has commercialized the world's largest number of 12 types of full AI stroke solutions, supporting the securing of the golden time through fast and accurate diagnosis, thereby responding to social needs.

The global stroke market is expected to grow to approximately 89 trillion KRW by 2030, with the U.S. market accounting for the largest share at 42%. The socioeconomic losses related to stroke patients in the U.S. amount to about 53 billion USD (approximately 70 trillion KRW). JLKE plans to officially enter the local market starting next year by establishing bases at 12 U.S. hospitals, including Harvard Medical School. The goal is to expand to 200 hospitals by 2025 and 1,200 hospitals by 2026.

He said, "The annual number of brain CT and MRI scans in the U.S. reaches about 120 million, which is about 10 times that of Korea, and the insurance reimbursement is about 1.4 million KRW (1,040 USD), 77 times higher than Korea's approximately 18,100 KRW," adding, "Supported by this high market potential, JLKE has set a sales target of 39 billion KRW for next year and is expected to surpass the break-even point (BEP) in the fourth quarter of 2024."

This content was produced with the assistance of AI translation services.